Scientists issue dire warning after dramatic behavioral shift in northern owls — here's why this change is so troubling
These changes could have lasting effects on communities that rely on healthy environments for farming, recreation, and everyday well-being.
The northern saw-whet owl, one of North America's smallest birds of prey, is migrating much farther than experts once believed. A report from Coastal Review shared insights from field biologist Noah Price, whose work confirms that these palm-sized owls are traveling hundreds of miles across the continent, often at night.
Thanks to decades of bird banding and tools like isotope analysis, researchers with Project Owlnet have discovered that these owls are navigating far-flung forests and mountain corridors.
This shift in migration patterns suggests not only that they rely on a wider range of habitats than once believed but also that they face more risks along the way.
When wildlife starts turning up in unfamiliar places, it usually means their usual homes are no longer meeting their needs. For northern saw-whets, that might mean trouble finding food, staying cool, or nesting safely in forests increasingly altered by development and rising temperatures.
As Coastal Review noted, more dominant species like the barred owl have already displaced native birds like the northern spotted owl in the Pacific Northwest.
If saw-whets move into new areas, they could unintentionally put pressure on other vulnerable species.
Owls help control rodent populations, making life easier for farmers, gardeners, and homeowners. When owl numbers dip or move away, communities may see more pests and less balance in local ecosystems. For rural families and agricultural workers, those shifts can hit close to home.
Changes in animal behavior also impact food security, economic stability, and public health.
Do you think your city has good air quality?
Definitely
Somewhat
Depends on the time of year
Not at all
Click your choice to see results and speak your mind.
Fortunately, researchers are working hard to understand and respond to these changes. Conservation groups involved in Project Owlnet are tracking owl movements through banding, recorded calls, and biological sampling to gather essential data.
You don't have to be a scientist to pitch in. Letting native plants grow, reducing chemical use, and leaving older trees standing can make your yard a more welcoming place for birds.
Communities are already seeing results. In Los Angeles, residents replaced thirsty lawns with native flowers to support birds and pollinators.
In Texas, people have rewilded their front yards, giving native species a place to rest and thrive.
Across the country, bee-friendly gardens are also helping pollinators bounce back, restoring balance in backyards and public parks alike.
These small actions can make a big difference. Creating bird-friendly habitats helps keep our ecosystems and communities healthier, more resilient, and better prepared for the changes ahead.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
10 minutes ago
- Medscape
Early Diagnosis and Treatment of Alzheimer's Disease
Alzheimer's disease (AD) is a progressive disease in which subtle symptoms of dementia gradually worsen over time. Clinicians are now encouraged to diagnose AD in early stages; not only can early treatment slow disease progression, but nearly 80% of Americans want to know whether they have AD before symptoms interfere with daily activities. In this panel ReCAP, Dr Michael Rafii, of University of Southern California, Los Angeles; and Dr Salvatore Napoli, of Neurology Center of New England, Foxborough, Massachusetts, discuss how early diagnosis of AD is essential because new disease-modifying therapies are most effective in early-stage AD. They explain that effective assessment begins with a structured clinical interview and neurologic exam, followed by a brief cognitive screening. If these results suggest mild cognitive impairment, further steps include a baseline brain MRI to rule out other causes. The experts discuss how advancements in Alzheimer's disease treatment have highlighted the importance of confirming amyloid buildup as a prerequisite for initiating certain therapies. Specifically, antiamyloid monoclonal antibody infusions, such as bimonthly lecanemab and monthly donanemab, require biomarker evidence of amyloid pathology in patients with early AD. Finally, the panelists emphasize the importance of real-world data collection, highlighted by ALZ-NET, a national registry designed to gather clinical, imaging, and safety data from patients with memory concerns or those receiving new AD therapies.
Yahoo
32 minutes ago
- Yahoo
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
24/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. 2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including a first trial result, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity. Upcoming Catalysts: Anticipated Trial Results in 2H 2025 1B/2 Trial – Ovarian Clear Cell Carcinoma (OCCC) Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5–10% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality. The Phase 1B/2 study of LB-100 plus the checkpoint inhibitor dostarlimab (GSK) is designed leverage LB-100's synergistic enhancement of immune checkpoint blockade. Status: Enrolled, with interim safety completed Upcoming Milestone: Preliminary safety and efficacy data expected Q4 2025 Potential Market Impact: Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies 1B/2 Trial – Advanced Soft Tissue Sarcoma (STS) Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains Phase 1B/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS. Status: Dose escalation completed. Upcoming Milestone: Safety report Q4 2025 Potential Market Impact: The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need 1B Trial – Metastatic Microsatellite Stable (MSS) Colon Cancer MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors. LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with+ atezolizumab (Roche) (an ICI), seeking to overcome immune resistance in this cold tumor type. Status: Trial open, first patients recruited Potential Market Impact: The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases Platform Potential and Market Opportunity LIXTE's strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform's potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence. Strong IP Position: Multiple issued and pending patents covering composition, methods of use, and combinations Pipeline Expansion: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma. Partnership Potential: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities Contact sales@ for Analyst Report coverage and other investor/public relations services. About LIXTE Biotechnology Holdings, Inc. LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. More information can be found at: 24/7 MARKET NEWS, INC DisclaimerPlease go to for further LIXT information and LIXT disclosure information. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. CONTACT: CONTACT: 24/7 Market News Editor@ in to access your portfolio
Yahoo
38 minutes ago
- Yahoo
Bad news: Study finds French fries can raise risk of this serious health condition by 20%
A new study published in the BMJ found that a regular French Fry habit can raise your type 2 diabetes risk by up to 20 percent. Harvard Public Health researchers found that the way potatoes are prepped makes a big difference in risk; those who ate baked, boiled, or mashed potatoes didn't see a big change in risk. Potatoes themselves are nutrient-dense, say experts, so it's best to consume them in the context of balanced meals. French fries are technically made from a vegetable, putting them in a weird grey zone of health. But while diving into a basket of fries has arguable mental health perks, it's probably not doing your physical health any solids. Now, brand new research suggests that fries could negatively impact your health in a very specific way. The study, which was recently published in The BMJ, found that a regular French fry habit can raise your risk of type 2 diabetes by up to 20%. While preparing potatoes differently than the fried version was better for type 2 diabetes risk, the researchers still found potatoes aren't the best starch for your health. While this doesn't mean you should never, ever have fries or potatoes again (thankfully!), experts say it's a good idea to keep a few things in mind about the taters going forward. Meet the experts: Christoph Buettner, MD, PhD, is chief of the division of endocrinology at Rutgers Robert Wood Johnson Medical School; Jessica Cording, RD, CDN, is author of The Little Book of Game-Changers; Mir Ali, MD, is medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA What exactly did the study find? For the study, Harvard Public Health researchers looked at detailed information on the diets and health status of more than 205,000 people who participated in three longitudinal studies in the US. Those studies tracked their information for more than 30 years, and included details on how much they ate of French fries, baked, boiled, and mashed potatoes, and whole grains. During the 30-year study period, more than 22,200 people were diagnosed with type 2 diabetes. And, when the researchers drilled down on the data, they found that those who ate three servings of fries a week had a 20% higher risk of being diagnosed with type 2 diabetes. On the flip side, people who consumed baked, boiled, or mashed potatoes didn't see a big impact on their risk of developing type 2 diabetes. One more thing to point out: people who had whole grains (think: farro, whole grain pasta, and whole grain bread) instead of baked, boiled, or mashed potatoes had a 4% lower risk of being diagnosed with type 2 diabetes. And when people had whole grains instead of fries, that risk dropped by 19%. Okay, but what's wrong with fries? The study didn't determine the exact reason this link exists, but there are a few things that could be behind this. One is that eating a lot of fries could lead to weight gain, which is a known risk factor for type 2 diabetes, says Jessica Cording, RD, CDN, author of The Little Book of Game-Changers. 'Due to their high palatability, it's easy for many people to eat a large serving very quickly,' she points out. It's also possible that people who eat a lot of fries have other dietary habits that can raise the risk of type 2 diabetes, including a lot of foods that are high in refined starches, fats, and sugars, says Christoph Buettner, MD, PhD, chief of the division of endocrinology at Rutgers Robert Wood Johnson Medical School. 'So, the issue is less about French fries specifically, and more about the broader dietary context in which they're often consumed,' he says. Cording agrees. 'There is something to be said for context – what other foods and beverages are most commonly consumed with fries compared to what someone might have with whole grains or with boiled, baked, or mashed potatoes?' she says. It's hard to say for sure what's behind this, says Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA. 'Frying changes the nutritional quality of the potatoes and undoes the benefits of potatoes,' he says. 'Deep frying also creates chemicals that are less healthy for you. It's probably a combination of all of these.' So are potatoes healthy? These findings don't mean you shouldn't touch a potato again. 'Potatoes are actually inherently very nutrient dense,' Cording says. 'They contain vitamin A and potassium, for example.' But she suggests enjoying potatoes in the context of a balanced meal that provides protein, healthy fats, and high-fibre, non-starchy vegetables. 'While an occasional serving of French fries isn't something I'd tell someone to worry about, the majority of the time, I'd encourage reaching for roasted or baked potatoes,' she says. Buettner agrees. 'It's fine to eat a few French fries with a lot of vegetables and some protein,' he says. 'But you should not eat them by itself or as snacks.' You Might Also Like 13 Buys To Help You Feel Great From £5 16 Speedo Swimsuits that Won't Flash Your Bum When Getting Swim-fit 11 Best Gym Trainers for Different Types of Workouts